ARBs + Statins for Dementia

(VISTA Trial)

This trial tests how well a specific combination of medications can manage high blood pressure and cholesterol in individuals at risk for developing dementia. Participants will take angiotensin receptor blockers for high blood pressure and either hydrophilic statins or a non-statin alternative for high cholesterol over six months. The trial focuses on individuals with certain genetic markers (APOE ε4) who have high cholesterol and blood pressure but do not yet have dementia. Suitable candidates are English-speaking individuals aged 50-75, with high cholesterol and blood pressure, and who carry the APOE ε4 gene. As a Phase 2 trial, this research measures the treatment's effectiveness in an initial, smaller group, offering participants a chance to contribute to important medical advancements.

The trial does not specify if you need to stop taking your current medications, but you cannot participate if you are using medications prescribed for dementia.

Previous studies have shown promising safety results for a type of medication called angiotensin receptor blockers (ARBs). Research indicates that most people tolerate ARBs well, and they are linked to a lower risk of developing dementia over time. For example, one study found that ARBs reduced the risk of Alzheimer's disease and similar dementias in people with high blood pressure, suggesting that ARBs might help protect brain health.

Hydrophilic statins, another type of medication, have also undergone extensive study. They are generally considered safe, with evidence showing they do not increase the risk of memory problems or dementia. In fact, some studies suggest that statins might even lower the risk of dementia, although results are mixed. These findings indicate that statins are unlikely to harm memory and are usually well-tolerated by patients.

Researchers are excited about this trial because it combines a proactive management approach with medications that target vascular risk factors, potentially influencing dementia progression. Angiotensin Receptor Blockers (ARBs) and hydrophilic statins are used to manage blood pressure and cholesterol, respectively, which are both linked to cognitive decline. Unlike standard treatments that may not focus on vascular health, this method uses pharmacist-led personalized care to optimize these specific factors. This tailored approach may offer a new avenue for slowing the progression of dementia, addressing underlying vascular issues that are often overlooked.

Research has shown that certain blood pressure medications, known as angiotensin receptor blockers (ARBs), can lower the risk of dementia. People taking ARBs have a reduced chance of developing Alzheimer's disease and other types of dementia compared to those using different blood pressure drugs. ARBs also appear to slow memory and thinking problems, helping to maintain brain health longer. In this trial, participants will receive pharmacist-led management of hypertension using ARBs.